What we do
The traditional, linear approach we have relied on for target discovery and drug development is slow, unpredictable and intrinsically disintegrated and disconnected.
But what if we reimagine drug discovery and development as a loop where each new project generates data that can inform all the projects that follow, making the process smaller and more predictive with each revolution?
This is what we’re building at Valo, every day.
Using machine learning algorithms and patient data, we are creating the first closed loop platform that will allow invaluable insights at every step of the drug discovery and development process.
That means we are enabling end-to-end human-centric insights and connecting all of the phases of drug discovery and development, making it faster, more connected, and more predictable.
In plain language, our Opal Computational Platform™ is positioned to advance therapeutic candidates in potentially half the time, at half the cost, and with fewer failures.
Valo uses human data in the context of human disease to identify novel human disease-associated targets and biomarkers based on genotype-phenotype-causality linkages discovered through advanced machine learning techniques and Valo’s expert scientists. This allows Valo to approach treating human disease without using traditional surrogates like cell models, mice, or similar. There is no better way to understand humans and their diseases than humans themselves.
Valo has created a unique “closed-loop” active learning, self-reinforcing, in silico and in lab-experimental platform that rapidly iterates to design drugs, making targeted and specific small molecules ‘engineerable’. We can go from zero to a molecule in hand in as little as 3 weeks. Valo can screen trillions of molecules computationally and billions of molecules empirically in a matter of days to weeks.
Valo has developed proprietary models for IND-enabling studies to drive translation success, including integrating it into molecule design, as well as simulations and prediction capabilities across the key drivers of clinical success: safety, efficacy, patient selection, and disease selection.
Opal Computational Platform™
Opal is our groundbreaking closed loop platform, which drives our capabilities and is the engine at the heart of our vision for next-generation drug discovery & development.